Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
Damage to the top OPEC producer's oil facilities ignited fears of supply disruption around the world and has sent crude prices soaring.Energyread more
The second-largest investor in Kraft Heinz Company discloses that it has again trimmed its stake in the food company.Marketsread more
Elliott Management may not see John Stankey as a future leader at AT&T, but bailing on him before he executes his integration plan has the potential for disaster.Technologyread more
Tension between the real estate start-up WeWork and SoftBank was not a central issue in the decision to delay an initial public offering, sources tell CNBC's David FaberThe Faber Reportread more
The service will debut in April with pricing to be announced closer to the launch data, NBCUniversal says.Technologyread more
A sharp drop in mortgage rates in August was clearly behind the confidence in September. The survey came with warning signs, however. Mortgage rates shot back up at the start...Real Estateread more
U.S. manufacturing output increased more than expected in August, boosted by a surge in machinery and primary metals production.Economyread more
The risk of a global recession is at its highest since August 2009, according to a survey of fund managers.Marketsread more
Chipotle rewards members will get the first chance to order carne asada.Restaurantsread more
Apple isn't trying to blow our minds with groundbreaking new features on the iPhone 11, but is making lots of little improvements each year, this year focusing on cameras and...Technologyread more
Shares of Teva Pharmaceuticals fell as much as 6 percent on Wednesday after the U.S. Patent Office invalidated two of the company's patents.
Mylan had filed a total of four claims related to Copaxone 40 mg. The two patents invalidated on Wednesday are owned by Yeda Research & Development and licensed to Teva. The involved parties are still waiting on a ruling for a third patent, which is expected by Sept. 1.
Earlier this month, the Patent Office had ruled that a fourth patent was not eligible for review due to procedural reasons. On Wednesday, Mylan said that it believes the favorable rulingundermines that earlier judgement. The company said it will be "pursuing all avenues to challenge" the earlier patent.
Teva CEO Erez Vigodman said in a statement, "We remain confident in the strength of our intellectual property surrounding COPAXONE 40mg." He also said that the company is "prepared to defend the full suite of our intellectual property... regardless of the time required."
Teva also said it plans to appeal the decision in the U.S. Court of Appeals for the Federal Circuit.
The stock recovered some losses and closed about 3 percent lower.